Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route

References

• Artursson P, Lindmark T. (1994). Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 11:1358–61
   PubMed Web of Science ®Google Scholar
• Aydin RST, Pulat M. (2012). 5-Fluorouracil encapsulated chitosan nanoparticles for ph-stimulated drug delivery: evaluation of controlled release kinetics. J Nanomater 12:144–56
   Google Scholar
• Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. (1997). Novel Hydrophilic chitosan–polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci 63:125–32
   Web of Science ®Google Scholar
• Chenite A, Gori S, Shive M, et al. (2006). Monolithic gelation of chitosan solutions via enzymatic hydrolysis of urea. Carbo Polym 64:419–24
   Web of Science ®Google Scholar
• Chopra S, Patil GV, Motwani SK. (2007). Release modulating hydrophilic matrix systems of losartan potassium: Optimization of formulation using statistical experimental design. Eur J Pharm Biopharm 66:73–82
   PubMed Web of Science ®Google Scholar
• Dash S, Murthy PN, Nath L, Chowdhury P. (2010). Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm 67:217–23
   PubMed Web of Science ®Google Scholar
• Davis SS. (1997). Biomedical applications of nanotechnology – implications for drug targeting and gene therapy. Trends Biotechnol 15:217–24
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Hanson LR, Frey WH. (2010). Intranasal delivery to the central nervous system: mechanism and experimental consideration. J Pharm Sci 99:1654–73
   PubMed Web of Science ®Google Scholar
• Dyer AM, Hinchcliff M. (2002). Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan NPs. Pharm Res 19:998–1008
   PubMed Web of Science ®Google Scholar
• Fan W, Yan W, Xu Z, Ni H. (2012). Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. Colloids Surf B: Biointer 90:21–7
   PubMed Web of Science ®Google Scholar
• Fernández M, Negro S, Slowing K, et al. (2011). An effective novel delivery strategy of RAS for Parkinson’s disease. Int J Pharm 419:271–80
   PubMed Web of Science ®Google Scholar
• Gallagher DA, Schrag A. (2008). Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. CNS Drugs 22:563–86
   PubMed Web of Science ®Google Scholar
• Gavini E, Rassu G, Ferraro L, et al. (2011). Influence of glutamate on the in vivo intranasal absorption of rokitamycin from microspheres. J Pharm Sci 100:1488–502
   PubMed Web of Science ®Google Scholar
• Genta I, Perugini P, Modena T, et al. (2003). Myconazole-loaded 6-oxychitin-chitosan microcapsules. Carbo Polym 52:11–18
   Web of Science ®Google Scholar
• Haque S, Shadab M, Fazil M, et al. (2012). Venlafaxine loaded chitosan NPs for brain targeting, Pharmacokinetic and pharmacodynamic evaluation. Carbo Polym 89:72–9
   PubMed Web of Science ®Google Scholar
• Illum L. (2000). Transport of drugs from the nasal cavity to central nervous system. Eur J Pharm Sci 11:1–18
   PubMed Web of Science ®Google Scholar
• Joshi SA, Chavhan SS, Sawant KK. (2010). Rivastigmine-loaded PLGA and PBCA NPs: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm 76:189–99
   PubMed Web of Science ®Google Scholar
• Kumar M, Misra A, Babbar AK, et al. (2008). Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm 358:285–91
   PubMed Web of Science ®Google Scholar
• Lakshmi MV, Rao S, Rao AL. (2010). Development and validation of RP-HPLC method for the estimation of RAS tablet dosage forms. Rasayan J Chem 3:621–4
   Google Scholar
• Md S, Khan RA, Mustafa G, et al. (2013). Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: Pharmacodynamic, Pharmacokinetic and Scintigraphy study in mice model. Eur J Pharm Sci 48:393–405
   PubMed Web of Science ®Google Scholar
• Mittal D, Ali A, Md S, et al. (2013). Insights in to direct nose to brain delivery: current status and future perspective. Drug Deliv 21:75–86
   PubMed Web of Science ®Google Scholar
• Mustafa G, Baboota S, Ali J, Ahuja A. (2012). Formulation development of chitosan coated intranasal ropinirole nanoemulsion for better management option of Parkinson: an in vitro-ex vivo evaluation. Curr Nanosci 8:348–60
   Web of Science ®Google Scholar
• Nussbaum RL, Ellis C. (2003). Alzheimer’s disease and Parkinson’s disease. N Engl Med 348:1356–64
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241–8
   PubMed Web of Science ®Google Scholar
• Pires A, Fortuna A, Alves G, Falcao A. (2009). Intranasal drug delivery: how, why and what for. J Pharm Sci 12:288–311
   Web of Science ®Google Scholar
• Ravi PR, Aditya N, Patil S, Cherian L. (2013). Nasal in-situ gels for delivery of rasagiline mesylate: improvement in bioavailability and brain localization. Drug Deliv 51:1–7
   Web of Science ®Google Scholar
• Schapira AHV. (2005). Present and future drug treatment for Parkinson’s disease. J Neurol Neurosurg Psychiatr 76:1472–8
   PubMed Web of Science ®Google Scholar
• Sofia P, Dimitrios B, Konstantinos A, et al. (2008). Chitosan nanoparticles loaded with dorzolamide and pramipexole. Carbo Polym 73:44–54
   Web of Science ®Google Scholar
• Taylor JP, Hardy J, Fischbeck KH. (2002). Toxic proteins in neurodegenerative disease. Science 296:1991–5
   PubMed Web of Science ®Google Scholar
• Wang X, Chi N, Tang X. (2008). Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm and Biopharm 70:735–40
   PubMed Web of Science ®Google Scholar
• Wen Z, Yan Z, Hu K, et al. (2011). Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson’s disease following intranasal administration. J Control Release 151:131–8
   PubMed Web of Science ®Google Scholar
• Zhang Q, Jiang X, Jiang W, et al. (2004). Preparation of nimodipine loaded microemulsion for intranasal delivery and evaluation of the targeting efficiency to brain. Int J Pharm 275:85–96
   PubMed Web of Science ®Google Scholar